Medicinal chemistry matters - A call for discipline in our discipline

Drug Discovery Today

Volumn 17, Issue 11-12, 2012, Pages 538-543

  Johnstone, Craig ^a  

^a Rapier Research Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; MK 8152; UNCLASSIFIED DRUG;

CANCER THERAPY; CHEMISTRY; COST EFFECTIVENESS ANALYSIS; HUMAN; LIPOPHILICITY; MEDICINAL CHEMISTRY; PHILOSOPHY; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; REVIEW; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE;

EID: 84861620361     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.01.010     Document Type: Short Survey

References (36)

1. T. Hoffmann, and C. Bishop The future of discovery chemistry: quo vadis? Academic to industrial-the maturation of medicinal chemistry to chemical biology Drug Discov. Today 15 2010 260 264
2. P. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discov. 6 2007 881 890
3. P. Leeson, and S. St-Gallay The influence of the organizational factor on compound quality in drug discovery Nat. Rev. Drug Discov. 10 2011 749 765
4. W.P. Walters What do chemists actually make? A 50-year retrospective J. Med. Chem. 54 2011 6405 6416
5. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Del. Rev. 23 1997 3 25
6. H. Van de Waterbeemd Property-based design: optimization of drug absorption and pharmacokinetics J. Med. Chem. 44 2001 1313 1333
7. M.J. Waring Lipophilicity in drug discovery Expert Opin. Drug Discov. 5 2010 235 248
8. J.D. Hughes Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 18 2008 4872 4875
9. A.L. Hopkins Ligand efficiency: a useful metric for lead selection Drug Discov. Today 9 2004 430 431
10. A.R. Leach Fragment screening: an introduction Mol. Biosyst. 2 2006 429 446
11. S.J. Teague The design of leadlike combinatorial libraries Angew. Chem. Int. Ed. 38 1999 3743 3748
12. M.J. Waring Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092 Med. Chem. Comm. 2 2011 775 779
13. M.M. Hann Molecular obesity, potency and other additions in drug discovery Med. Chem. Commun. 2 2011 349 355
14. F. Lovering Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 52 2009 6752 6756
15. D. McKerrecher Design of a potent, soluble glucokinase activator with excellent in vivo activity Bioorg. Med. Chem. Lett. 16 2006 2705 2709
16. S.N.L. Bennett Discovery of a series of indan carboxylic acid glycogen phosphorylase inhibitors Bioorg. Med. Chem. Lett. 20 2010 3511 3514
17. M.J. Waring Defining optimum lipophilicity and molecular weight ranges for drug candidates - molecular weight dependent lower log D limits based on permeability Bioorg. Med. Chem. Lett. 19 2009 2844 2851
18. T.W. Johnson Using the Golden Triangle to optimize clearance and oral absorption Bioorg. Med. Chem. Lett. 19 2009 5560 5564
19. A. Linusson Statistical molecular design, parallel synthesis and biological evaluation of a library of thrombin inhibitors J. Med. Chem. 44 2001 3424 3439
20. E. Griffen Matched molecular pairs as a medicinal chemistry tool J. Med. Chem. 2011 10.1021/jm200452d
21. T.J. Ritchie The graphical representation of ADME-related molecule properties for medicinal chemists Drug Discov. Today 16 2011 65 72
22. M.D. Brodney Project-focused activity and knowledge tracker: a unified data analysis, collaboration and workflow tool for medicinal chemistry project teams J. Chem. Inf. Model. 49 2009 2639 2649
23. K.D. Stewart Drug Guru: a computer software program for drug design using medicinal chemistry rules Bioorg. Med. Chem. 14 2006 7011 7022
24. H.N. Weller Application of lean manufacturing concepts to drug discovery: rapid analogue library synthesis J. Combin. Chem. 8 2006 664 669
25. S. Andersson Making medicinal chemistry more effective - application of lean sigma to improve processes, speed and quality Drug Discov. Today 14 2009 598 604
26. C.W. Lindsley Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors Bioorg. Med. Chem. Lett. 15 2005 761 764
27. T. Siu The design and synthesis of potent and cell-active allosteric dual Akt-1 and 2 inhibitors devoid of hERG activity Bioorg. Med. Chem. Lett. 18 2008 4191 4194
28. M.J. Waring, and C. Johnstone A quantitative assessment of hERG liability as a function of lipophilicity Bioorg. Med. Chem. Lett. 17 2007 1759 1764
29. H. Zhao Lead optimisation in the nondruglike space Drug Discov. Today 16 2011 158 163
30. E. Perola An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs J. Med. Chem. 53 2010 2986 2997
31. C.E. Mowbray Pyrazole NRTIs: selection of UK-453,061 (lersivirine) as a development candidate Bioorg. Med. Chem. Lett. 19 2009 5857 5860
32. I. Sharnovsky Overcoming undesirable hERG potency of chemokine receptor antagonists using baseline lipophilicity relationships J. Med. Chem. 51 2008 1162 1178
33. J.J. Cui Structure-based drug design of Crizotinib (PF-02341066) a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 54 2011 6342 6363
34. L.J.S. Knutsen Drug discovery management, small is beautiful: why a number of companies get it wrong Drug Discov. Today 16 2011 476 484
35. C. Johnstone Creativity, innovation and lean sigma: a controversial combination? Drug Discov. Today 15 2010 50 57
36. J. Delaney Modelling iterative compound optimisation using a self-avoiding walk Drug Discov. Today 14 2009 198 207